Immix Biopharma (IMMX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.19
- Surprise
- —
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Immix Biopharma Announces Oral Presentation of NXC-201 Interim Clinical Trial Results at ASH 2026 — fiscal.ai, 2026-11-04
- Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15 — benzinga, 2026-11-04
Where TrendMatrix's rating stands now
TrendMatrix currently rates IMMX Sell at 5.6/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Pipeline: NXC-201
- Concentration risk — Supplier: third-party CMOs
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.06
- Price target
- $20.92
- Stop
- $7.50
- Upside to target
- +159.6%
- Reward-to-risk
- 10.6:1
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
IMMX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $668.2M
- P/E (fwd)
- -8.5
- 52-week range
- $2.89–$15.10
- Off 52-week high
- 46.6%
- RSI (14)
- 48
- Volume vs avg
- 1.14×
- Score today
- 5.6/10